摘要
目的：本研究旨在评价头孢唑兰对临床分离菌株的体外抗菌作用,为头孢唑兰的临床使用提供参考依据。方法：采用琼脂双倍稀释法测定头孢唑兰对14类127株呼吸系统和泌尿系统感染分离出的病原菌株的体外抗菌活性,并与已经上市的3种常用抗菌药物进行了体外抗菌活性比较,试验平行3次,观察结果。结果：头孢唑兰对7种临床分离G＋菌株包括金黄色葡萄球菌、化脓性链球菌、肺炎链球菌、无乳链球菌、甲氧西林敏感表皮葡萄球菌（MSSE）、甲氧西林敏感金黄色葡萄球菌（MSSA）的MIC50均在0.125-1μg·ml^-1之间,MIC90在0.5-8μg·ml^-1之间;对肺炎克雷伯菌、大肠埃希菌、奇异变形杆菌、流感嗜血杆菌、产气肠杆菌、铜绿假单胞菌、阴沟肠杆菌的MIC均值分别为0.23,0.21,0.42,4.74,6.31,8.75,16.35μg·ml^-1。结论：头孢唑兰对14类127株呼吸系统和泌尿系统感染菌株的体外抗菌活性明显,具有显著的体外抗菌活性。
Objective： To evaluate the in vitro antibacterial effect of cefozopran on the clinical isolate bacteria to provide reference for its clinical use. Methods： An AGAR double dilution method was used to determine the in vitro antibacterial effect of cefozopran on 14 classes,127 strains pathogenic bacteria isolated from the respiratory and urinary tract infections,and compared with that of 3 commonly used marketed antimicrobial agents. The parallel experiments were repeated for 3 times to observe the final results. Results： MIC50 of cefozopran against 7 kinds of clinical isolate G＋strains including Staphylococcus aureus,Pyogenic streptococcus, Streptococcus pneumoniae, Streptococcus, Methicillin-sensitive Staphylococcus aureus（ MSSA） and Methicillin-sensitive Staphylococcus epidermidis（ MSSE） was within the range of 0. 125 - 1 μg ·ml^-1 and MIC90 was within the range of 0. 5 - 8 μg · ml^-1. Average MIC of cefozopran against Klebsiella pneumoniae,Escherichia coli,Proteus mirabilis,Haemophilus influenzae,Enterobacter aerogenes,Pseudomonas aeruginosa and Enterobacter cloacae was 0. 23,0. 21,0. 42,4. 74,6. 31,8. 75 and 16. 35 μg ·ml^-1,respectively. Conclusion： Cefozopran shows obvious in vitro antibacterial effect on respiratory and urinary tract infection strains with significant antimicrobial activity in vitro.
出处
《中国药师》
CAS
2014年第12期2162-2164,共3页
China Pharmacist
